"... Relationships with the pharmaceutical industry
Califf worked very closely with pharmaceutical companies at the Duke clinical trials center "convincing them to do large, expensive, and, for Duke, profitable clinical trials."[12] He was a paid consultant for Merck Sharp & Dohme, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, and Eli Lilly per ProPublica from 2009 to 2013. The largest consulting payment was $87,500 by Johnson & Johnson in 2012, and "most of funds for travel or consulting under $5,000", which has been called "minimal for a physician of his stature".[13] From 2013-2014 he was paid a total of $52,796, the highest amount was $6,450 from Merck Sharp & Dohme, followed by Amgen, F. Hoffmann-La Roche AG, Janssen Pharmaceutica, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb and AstraZeneca.[14] He was the Director of Portola Pharmaceuticals, Inc. from July 2012 to January 26, 2015,[13] An advisor of Proventys, Inc., Chairman of the medical advisory board of Regado Biosciences, Inc. and has been a member of the medical advisory board since June 2, 2009, and a member of the clinical advisory board of Corgentech Inc.[15] Forbes wrote that his close ties to the drug industry were why he was not nominated for the FDA Commissioner position in 2009.[12] Califf's ties to the pharmaceutical industry were criticized by the magazine The American Prospect,[16] and Democratic Senators Bernie Sanders and Joe Manchin who announced their intention to vote against his 2021 renomination.[17] ..."
.
Appointed by Barry O to the FDA. During Potatus's nomination of Califf there was lots of pushback due, at least in part, to Califf's position regarding abortion (easing access to abortion pills) and his role in facilitating opioid addictions and deaths.
Some background on this Dr. Califf. (From wiki):
.
"... Relationships with the pharmaceutical industry
Califf worked very closely with pharmaceutical companies at the Duke clinical trials center "convincing them to do large, expensive, and, for Duke, profitable clinical trials."[12] He was a paid consultant for Merck Sharp & Dohme, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, and Eli Lilly per ProPublica from 2009 to 2013. The largest consulting payment was $87,500 by Johnson & Johnson in 2012, and "most of funds for travel or consulting under $5,000", which has been called "minimal for a physician of his stature".[13] From 2013-2014 he was paid a total of $52,796, the highest amount was $6,450 from Merck Sharp & Dohme, followed by Amgen, F. Hoffmann-La Roche AG, Janssen Pharmaceutica, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb and AstraZeneca.[14] He was the Director of Portola Pharmaceuticals, Inc. from July 2012 to January 26, 2015,[13] An advisor of Proventys, Inc., Chairman of the medical advisory board of Regado Biosciences, Inc. and has been a member of the medical advisory board since June 2, 2009, and a member of the clinical advisory board of Corgentech Inc.[15] Forbes wrote that his close ties to the drug industry were why he was not nominated for the FDA Commissioner position in 2009.[12] Califf's ties to the pharmaceutical industry were criticized by the magazine The American Prospect,[16] and Democratic Senators Bernie Sanders and Joe Manchin who announced their intention to vote against his 2021 renomination.[17] ..."
.
Appointed by Barry O to the FDA. During Potatus's nomination of Califf there was lots of pushback due, at least in part, to Califf's position regarding abortion (easing access to abortion pills) and his role in facilitating opioid addictions and deaths.
.
https://nypost.com/2022/02/15/senate-narrowly-confirms-robert-califf-to-head-fda/